PerpEquities

BioNTech SE (BNTX) cash flow statement

NASDAQ · Healthcare · Biotechnology · 7,807 employees · CEO Ugur Sahin

Price
$88.17 -1.08%
Market cap
$22.1B
Enterprise value
€10.2B
Last report
Q2 '26 filed 2026-08-04
Next report
2026-11-03

In Q2 '26 BioNTech SE (BNTX) generated €11M of operating cash flow, invested €56.6M in capital expenditure and kept -€44.8M of free cash flow. Over the last four quarters free cash flow was €518M.

Cash flow

Cash flowTrendQ3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Operating
Net income€227M€492M-€342M-€870M€218M€277M-€438M-€439M-€33.5M-€302M-€541M-€834M
Depreciation & amortization€41.3M€78.8M€38.3M€49.9M€44.4M€165M€42.8M€51M€124M€163M€123M€266M
Stock-based compensation€15.5M€0€0€0€0€0€0€0€0€0€0€0
Deferred income tax€0€0€0€0-€56.5M€45.5M-€34M-€23M€61.4M€67.5M-€39M€0
Change in working capital€639M-€1.78B€241M€2.55B-€723M-€745M-€438M€570M€730M-€215M€67.3M€607M
Other non-cash items-€112M€2.05B-€282M€24.8M-€170M-€244M€45.5M-€27.5M-€27.9M€586M-€38.8M-€27.8M
Operating cash flow€811M€851M-€344M€1.76B-€688M-€501M-€822M€132M€855M€299M-€428M€11M
Investing
Capital expenditure-€54M€292M-€149M-€152M-€90.9M-€100M-€651M€568M-€69.1M-€63.4M-€80.2M-€56.6M
Acquisitions-€337M€4.7M€0€216K€326K€763K-€82.1M-€2.17M€205K€256M€1.63M€3.47M
Purchases of investments-€1.05B-€3.95B-€5.31B-€2.62B-€3.23B-€2.29B-€2.64B-€1.9B-€3.4B-€4.26B-€1.58B-€2.1B
Sales / maturities of investments€303M€1.31B€2.96B€2.52B€3.16B€3.04B€4.68B€1.93B€2.47B€1.44B€4.35B€2.05B
Other investing-€97.2M-€489M€0€0€0€0€0-€622M€0€0€0€0
Investing cash flow-€1.23B-€2.84B-€2.5B-€249M-€163M€649M€1.31B-€26.7M-€996M-€2.63B€2.69B-€104M
Financing
Net debt issued / repaid-€9.3M€215K€0€0-€7.81K-€9.02K-€4.74M-€4.18M-€1.68M-€1.88M€38.9M€32.7M
Share buybacks-€302M€9.44M€0€0€0€0€0€0€0€0€0-€132M
Other financing (incl. tax on vested shares)€0-€12.8M-€8.47M-€24.7M-€8.66M-€8.08M-€9.79M-€10.8M-€12.4M-€12.1M-€12.1M-€11.5M
Financing cash flow-€311M-€3.17M-€8.47M-€24.7M-€8.66M-€8.09M-€14.5M-€14.9M-€14M-€14M€26.8M-€111M
Summary
FX effect on cash€61.2M€583M-€336M-€59.3M€479M-€773M€417M€963M-€40.4M-€79.6M-€175M-€71.8M
Net change in cash-€671M-€1.4B-€3.19B€1.43B-€380M-€633M€893M€1.05B-€196M-€2.42B€2.12B-€276M
Free cash flow (OCF - capex)€660M€1.14B-€493M€1.61B-€779M-€602M-€1.47B€700M€811M€238M-€486M-€44.8M

Standardised from the company's filings; outflows and costs keep the sign the provider reports. Hover a period for its end date. Amounts in EUR.

Operating cash flow, capex, free cash flow

quarterly

Uses of cash vs operating cash flow

fiscal years

Share count and EPS

quarterly, diluted

The other statements

Sources

Statements, segment revenue, metrics and estimates are standardised from the company's filings.

Data as of 2026-11-02 · Amounts in EUR as reported; price and market cap in USD.